High-stability doxorubicin liposome injection preparation and preparation process thereof

By using distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol structure and buffer regulation in doxorubicin liposomes, combined with stabilizers, the problem of poor liposome stability is solved and the doxorubicine liposomes is achieved High stability storage and slow release of liposomes of Bacteria improves the efficacy of the drug.

CN118986885APending Publication Date: 2024-11-22CHANGZHOU JINYUAN PHARM MFG CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202410978761.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing doxorubicin liposomes have poor stability during storage, resulting in a decrease in drug efficacy and aggravated side effects, making it difficult to achieve long-term stable storage.

Method used

The chemical stability of liposomes is enhanced by distearylphosphatidylethanolamine-polyethylene glycol-tocopherol structure, and the pH is adjusted through components such as citric acid-sodium citrate buffer and histidine, combining with 2 whale Wax phosphate and phosphatidylserine act as stabilizers to enhance the physical stability and drug loading of liposomes.

Benefits of technology

High stability storage of doxorubicin liposomes is achieved, extending the release time of the drug in the blood, reducing side effects, and improving the efficacy and drug loading.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004955383750000081
    Figure BDA0004955383750000081
Patent Text Reader

Abstract

The invention relates to the technical field of liposome preparations, in particular to a high-stability doxorubicin liposome injection preparation and a preparation process thereof. Comprising the following steps: S1, preparing doxorubicin liposome; S11, preparing distearoyl phosphatidyl ethanolamine-polyethylene glycol-tocopherol; s12, hydrogenated lecithin, distearoyl phosphatidyl ethanolamine-polyethylene glycol-tocopherol, cholesterol, absolute ethyl alcohol and ammonium sulfate are sheared, mixed and filtered, and a blank liposome crude product is obtained; s13, carrying out dialysis treatment on the blank liposome crude product to obtain a blank liposome suspension; s14, adding a doxorubicin solution into the blank liposome suspension, heating and preserving heat, and then performing sterilization treatment and reduced-pressure rotary evaporation to obtain doxorubicin lipid; and S2, preparing the doxorubicin liposome and the compound water for injection into a high-stability doxorubicin liposome injection preparation, and storing for later use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of liposome preparations, in particular to a high-stability doxorubicin liposome injection preparation and a preparation process thereof. Background Art

[0002] Doxorubicin is an anthracycline antibiotic, an anti-mitotic cytotoxic drug, which can effectively induce remission of a variety of malignant tumors, including acute leukemia, lymphoma, soft tissue and bone sarcoma, childhood malignant tumors and adult solid tumors, especially for breast cancer and lung cancer. Because the original doxorubicin is unstable, the commercially available doxorubicin is generally in the form of doxorubicin hydrochloride; but at the same time, doxorubicin hydrochloride is toxic to nerves, so the existing technology generally encapsulates it in liposomes with methoxy polyethylene glycol on the surface, while balancing the toxicity, further protecting the liposomes from recognition by mononuclear macrophages and prolonging their time in blood circulation.

[0003] However, most of the doxorubicin liposomes obtained by the prior art cannot achieve long-term stable storage after being prepared into storage liquid, that is, the storage stability is poor, which will undoubtedly reduce the efficacy of the drug and aggravate the side effects. To achieve long-term stable storage of drugs, liposomes need to have excellent stability, and their stability is specifically manifested in chemical stability and physical stability. The combination of the two has an important impact on the drug loading inside the liposome. Among them, chemical stability is mainly reflected in whether the phospholipids of the liposome are easily oxidized. If they are easily oxidized, it will cause drug leakage, and then it will degrade and gradually lose drug activity; physical stability is mainly reflected in the leakage rate of liposomes to drugs. The greater the leakage rate, the more leakage, and a large amount of drugs will also be degraded and lose drug activity. That is to say, the poor stability of the liposome will lead to a decrease in the drug loading inside the liposome, which will directly affect the clinical application dose, so that the drug cannot meet clinical needs.

[0004] In summary, the present invention provides a highly stable doxorubicin liposome injection preparation, which has optimal storage stability, can stably retain drug properties for a long time, meets clinical needs, and is of great significance. Summary of the invention

[0005] The object of the present invention is to provide a high-stability doxorubicin liposome injection preparation and a preparation process thereof, so as to solve the problems raised in the above background technology.

[0006] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0007] A preparation process of a high-stability doxorubicin liposome injection preparation comprises the following steps:

[0008] S1: Preparation of doxorubicin liposomes:

[0009] S11: (1) adding 20 to 25 parts of distearoyl phosphatidylethanolamine-polyethylene glycol-carboxyl to 200 parts of dichloromethane by weight, stirring and dissolving, adding 5 to 8 parts of δ-tocopherol, 0.5 to 1 part of a catalyst, and 4 to 5 parts of a catalyst promoter, reacting at room temperature in the dark for 2 to 12 hours, ending the reaction, filtering, removing the filter residue, and collecting the filtrate; (2) pouring the filtrate into 200 parts of ether, standing at -20 to -5°C for 3 to 6 hours, filtering, removing the filtrate, collecting the filter residue, and drying to obtain distearoyl phosphatidylethanolamine-polyethylene glycol-tocopherol;

[0010] S12: (1) adding 35-45 parts of hydrogenated lecithin, 10-15 parts of distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol, and 10-15 parts of cholesterol to 150 parts of anhydrous ethanol by weight, stirring and dissolving, to obtain a lipid solution; (2) heating the lipid solution to 50-65° C. in a water bath, high-speed shearing at a speed of 10,000-15,000 r / min, and adding 200 parts of 200-250 mmol / L ammonium sulfate solution thereto, and after high-speed shearing for 10-30 min, extruding and filtering 2-3 times using an extruder to obtain a crude blank liposome;

[0011] S13: dialyzing the blank liposome crude product with buffer A at room temperature to obtain a blank liposome suspension;

[0012] S14: (1) adding doxorubicin hydrochloride to deionized water to prepare a doxorubicin solution with a concentration of 3-5 wt %; (2) adding the doxorubicin solution to the blank liposome suspension, mixing well, heating the suspension to 55-65° C. in a water bath for 10-30 min, then cooling the suspension in an ice water bath to stop drug loading, sterilizing the suspension, and finally performing vacuum rotary evaporation at 25-30° C. to obtain doxorubicin liposomes, which were then stored at 2-5° C. for later use;

[0013] S2: After preparing the doxorubicin liposome and compound water for injection into a high-stability doxorubicin liposome injection preparation, place it at 2-5°C and seal it in the dark for future use.

[0014] Furthermore, the catalyst includes but is not limited to any one of 4-dimethylaminopyridine, 4-pyrrolidinylpyridine, and 1-hydroxyphenyltriazole.

[0015] Furthermore, the catalyst promoter includes but is not limited to any one of N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

[0016] 4-Dimethylaminopyridine is a highly efficient catalyst, mainly used in organic reactions such as acylation of alcohols, phenols, and amines and phenol exchange. Compared with traditional acylation catalysts, its catalytic acylation reaction has the advantages of fast reaction speed, low reaction temperature, and high yield. Under the synergistic effect of N,N'-dicyclohexylcarbodiimide, 4-dimethylaminopyridine can catalyze the phenolation reaction of hindered acids and alcohols (or phenols) and has stronger reactivity.

[0017] Furthermore, the buffer A comprises the following components: by weight, 5-10 parts of sodium citrate, 2-5 parts of histidine, 5-15 parts of sucrose, and 100 parts of deionized water, and citric acid is added to adjust the pH to 5.5-6.5.

[0018] Furthermore, the extruder is a liposome extruder, wherein the pore size of the filter membrane used is 0.05-0.45 μm.

[0019] Furthermore, the ratio of the blank liposome crude product to buffer A is 3 g:100 mL.

[0020] Furthermore, the volume ratio of the blank liposome suspension to the doxorubicin solution is 10:1.

[0021] Distearoylphosphatidylethanolamine-polyethylene glycol is a polyethylene glycol modification, which has both hydrophilicity and flexibility, can form a hydration film on the surface of liposomes, hinder the adsorption of plasma components and liposome surfaces, thereby reducing the uptake of liposomes by the reticuloendothelial system, prolonging the time of liposomes in systemic circulation, and then slowly releasing the drugs in the liposomes for better absorption and utilization; δ-tocopherol is a harmless antioxidant to the human body, which can play a positive role in blocking liposome oxidation. Therefore, in the present invention, in order to enhance the chemical stability of liposomes, distearoylphosphatidylethanolamine-polyethylene glycol-carboxyl containing distearoylphosphatidylethanolamine-polyethylene glycol structure and δ-tocopherol are reacted and grafted to prepare distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol, so as to achieve the purpose of enhancing the chemical stability of liposomes.

[0022] Considering that tocopherol is unstable under alkaline conditions and in order to avoid oxidation of blank liposomes during dialysis treatment, the buffer solution was prepared accordingly in the scheme, and the crude blank liposomes were dialyzed using a citric acid-sodium citrate buffer. At the same time, histidine was added to the buffer to further coordinately adjust the pH and weaken the effect of pH changes on liposomes; sucrose was added to the liposomes to play a shaping role, avoid fusion of the liposome membrane layer, further stabilize the liposome structure, and thus improve its encapsulation rate and drug loading. Finally, liposomes with stable structure, high encapsulation rate, and high drug loading were obtained, and their long-term storage performance was excellent.

[0023] Furthermore, the composite water for injection is obtained by mixing buffer solution B and water for injection in a volume ratio of 1:(1-2).

[0024] Furthermore, the buffer solution B comprises the following components: by weight, 1 to 2 parts of sodium citrate, 0.5 to 2 parts of glucose, 2 to 3 parts of stabilizer, and 25 parts of deionized water, and citric acid is added to adjust the pH to 5.5 to 6.5.

[0025] Furthermore, the stabilizer is obtained by mixing dicetyl phosphate and phosphatidylserine in a mass ratio of 1:1.

[0026] Furthermore, in the high-stability doxorubicin liposome injection preparation, the concentration of doxorubicin liposome is 2 mg / mL.

[0027] In order to ensure the stability of doxorubicin liposomes, the present invention prepares a composite water for injection, which contains buffer B. The citric acid in the buffer B further ensures the oxidation resistance of the doxorubicin liposomes and ensures their chemical stability. In the embodiment, the stabilizer is dicetyl phosphate and phosphatidylserine, both of which can be adsorbed and combined on the surface of the liposomes to enhance the stability of the liposomes, effectively reduce the leakage rate during storage, and ensure their physical stability. After being injected into the patient's body, the two can also enhance the targeting of the doxorubicin liposomes to reduce the toxic effects of the drug, thereby improving the efficacy of the drug.

[0028] Compared with the prior art, the beneficial effects achieved by the present invention are:

[0029] (1) The present invention considers the chemical stability and physical stability of liposomes and comprehensively prepares doxorubicin liposomes with good stability; in terms of chemical stability, the possibility of liposome oxidation is reduced from the preparation of blank liposomes to the preparation of injection preparations; in terms of physical stability, the structural stability of the doxorubicin liposome membrane layer is enhanced, and its leakage rate is effectively reduced;

[0030] (2) The doxorubicin liposomes have good encapsulation efficiency and drug loading capacity, and their structure is stable. They will not be ruptured by oxidation, ice crystals, etc. during storage, resulting in significant drug leakage and reduced clinical efficacy.

[0031] (3) The doxorubicin liposome can be slowly released in the blood and has a longer drug action time;

[0032] (4) The doxorubicin liposome has a certain targeting property, which can reduce the side effects of the drug and has a better drug efficacy. DETAILED DESCRIPTION

[0033] The following is a preferred implementation of the embodiment of the present invention. Obviously, the described embodiment is only a part of the embodiment of the present invention, not all of the embodiments. For ordinary technicians in this technical field, all other embodiments obtained by ordinary technicians in this field without creative work without departing from the principle of the embodiment of the present invention are within the scope of protection of the present invention.

[0034] Example 1: Preparation process of a high-stability doxorubicin liposome injection preparation:

[0035] S1: Preparation of doxorubicin liposomes:

[0036] S11: (1) Add 22 parts of distearoyl phosphatidylethanolamine-polyethylene glycol-carboxyl to 200 parts of dichloromethane by weight, stir and dissolve, then add 7 parts of δ-tocopherol, 0.8 parts of 4-dimethylaminopyridine and 4.5 parts of N,N'-dicyclohexylcarbodiimide, and react for 10 hours at room temperature in the dark. After the reaction is terminated, the residue is removed by filtration and the filtrate is collected; (2) Pour the filtrate into 200 parts of ether, let stand at -10°C for 5 hours, filter and remove the filtrate, collect the residue and dry to obtain distearoyl phosphatidylethanolamine-polyethylene glycol-tocopherol;

[0037] S12: (1) adding 40 parts of hydrogenated lecithin, 12 parts of distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol and 12 parts of cholesterol to 150 parts of anhydrous ethanol by weight, stirring and dissolving to obtain a lipid solution; (2) heating the lipid solution to 60°C in a water bath, and then high-speed shearing at a speed of 13500 r / min, while adding 200 parts of 225 mmol / L ammonium sulfate solution thereto, and after high-speed shearing for 20 minutes, extruding and filtering three times using an extruder to obtain a crude blank liposome;

[0038] S13: At room temperature, the crude blank liposome was dialyzed with buffer A (by weight, 8 parts of sodium citrate, 4 parts of histidine, 10 parts of sucrose, 100 parts of deionized water, and citric acid was added to adjust the pH to 6) (the ratio of the two was 100 mL: 3 g) to obtain a blank liposome suspension;

[0039] S14: (1) adding doxorubicin hydrochloride to deionized water to prepare a doxorubicin solution with a concentration of 4 wt %; (2) adding the doxorubicin solution to the blank liposome suspension (the volume ratio of the two is 10:1), mixing well, heating the suspension to 60° C. in a water bath for 30 min, then cooling the suspension in an ice water bath to stop drug loading, sterilizing the suspension, and finally performing vacuum rotary evaporation at 25° C. to obtain doxorubicin liposomes, which were stored at 4° C. for future use;

[0040] S2: Prepare a high-stability doxorubicin liposome injection preparation by mixing doxorubicin liposomes and composite water for injection (buffer B and water for injection are mixed in a volume ratio of 1:1; wherein buffer B comprises the following components: 2 parts of sodium citrate, 1 part of glucose, 2.5 parts of stabilizer, 25 parts of deionized water, by weight, citric acid is added to adjust the pH to 6, and the stabilizer is prepared by mixing dicetyl phosphate and phosphatidylserine in a mass ratio of 1:1), place it in an environment of 4°C, seal it and keep it away from light for later use.

[0041] Example 2: Preparation process of a high-stability doxorubicin liposome injection preparation:

[0042] S1: Preparation of doxorubicin liposomes:

[0043] S11: (1) Add 22 parts of distearoyl phosphatidylethanolamine-polyethylene glycol-carboxyl to 200 parts of dichloromethane by weight, stir and dissolve, then add 5 parts of δ-tocopherol, 0.8 parts of 4-dimethylaminopyridine and 4.5 parts of N,N'-dicyclohexylcarbodiimide, and react for 10 hours at room temperature in the dark. After the reaction is terminated, the residue is removed by filtration and the filtrate is collected; (2) Pour the filtrate into 200 parts of ether, let stand at -10°C for 5 hours, filter and remove the filtrate, collect the residue and dry to obtain distearoyl phosphatidylethanolamine-polyethylene glycol-tocopherol;

[0044] S12: (1) adding 40 parts of hydrogenated lecithin, 10 parts of distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol and 12 parts of cholesterol to 150 parts of anhydrous ethanol by weight, stirring and dissolving to obtain a lipid solution; (2) heating the lipid solution to 60°C in a water bath, and then high-speed shearing at a speed of 13500 r / min, while adding 200 parts of 200 mmol / L ammonium sulfate solution thereto, and after high-speed shearing for 20 minutes, extruding and filtering three times using an extruder to obtain a blank liposome crude product;

[0045] S13: At room temperature, the crude blank liposome was dialyzed with buffer A (by weight, 5 parts of sodium citrate, 2 parts of histidine, 5 parts of sucrose, 100 parts of deionized water, and citric acid was added to adjust the pH to 6) (the ratio of the two was 100 mL: 3 g) to obtain a blank liposome suspension;

[0046] S14: (1) adding doxorubicin hydrochloride to deionized water to prepare a doxorubicin solution with a concentration of 3 wt %; (2) adding the doxorubicin solution to the blank liposome suspension (the volume ratio of the two is 10:1), mixing well, heating the suspension to 60° C. in a water bath for 30 min, then cooling the suspension in an ice water bath to stop drug loading, sterilizing the suspension, and finally performing vacuum rotary evaporation at 25° C. to obtain doxorubicin liposomes, which were then stored at 4° C. for future use;

[0047] S2: Prepare a high-stability doxorubicin liposome injection preparation by mixing doxorubicin liposomes and composite water for injection (buffer B and water for injection are mixed in a volume ratio of 1:1; wherein buffer B comprises the following components: by weight, 1 part of sodium citrate, 0.5 part of glucose, 2 parts of stabilizer, 25 parts of deionized water, citric acid is added to adjust the pH to 6, and the stabilizer is prepared by mixing dicetyl phosphate and phosphatidylserine in a mass ratio of 1:1), place it in an environment of 4°C, seal it and keep it away from light for later use.

[0048] Example 3: Preparation process of a high-stability doxorubicin liposome injection preparation:

[0049] S1: Preparation of doxorubicin liposomes:

[0050] S11: (1) Add 20 parts of distearoyl phosphatidylethanolamine-polyethylene glycol-carboxyl to 200 parts of dichloromethane by weight, stir and dissolve, add 8 parts of δ-tocopherol, 0.8 parts of 4-dimethylaminopyridine, and 4.5 parts of N,N'-dicyclohexylcarbodiimide, and react for 10 hours at room temperature in the dark. End the reaction, filter, remove the filter residue, and collect the filtrate; (2) Pour the filtrate into 200 parts of ether, let stand at -10°C for 5 hours, filter, remove the filtrate, collect the filter residue, and dry to obtain distearoyl phosphatidylethanolamine-polyethylene glycol-tocopherol;

[0051] S12: (1) adding 40 parts of hydrogenated lecithin, 15 parts of distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol and 12 parts of cholesterol to 150 parts of anhydrous ethanol by weight, stirring and dissolving to obtain a lipid solution; (2) heating the lipid solution to 60°C in a water bath, and then subjecting it to high-speed shearing at a speed of 13500 r / min, while adding 200 parts of 250 mmol / L ammonium sulfate solution thereto, and after high-speed shearing for 20 minutes, extruding and filtering it three times using an extruder to obtain a crude blank liposome;

[0052] S13: At room temperature, the crude blank liposome was dialyzed with buffer A (by weight, 10 parts of sodium citrate, 5 parts of histidine, 15 parts of sucrose, 100 parts of deionized water, and citric acid was added to adjust the pH to 6) (the ratio of the two was 100 mL: 3 g) to obtain a blank liposome suspension;

[0053] S14: (1) adding doxorubicin hydrochloride to deionized water to prepare a doxorubicin solution with a concentration of 5 wt %; (2) adding the doxorubicin solution to the blank liposome suspension (the volume ratio of the two is 10:1), mixing well, heating the suspension to 60° C. in a water bath for 30 min, then cooling the suspension in an ice water bath to stop drug loading, sterilizing the suspension, and finally performing vacuum rotary evaporation at 25° C. to obtain doxorubicin liposomes, which were then stored at 4° C. for future use;

[0054] S2: Prepare a high-stability doxorubicin liposome injection preparation by mixing doxorubicin liposomes and composite water for injection (buffer B and water for injection are mixed in a volume ratio of 1:1; wherein buffer B comprises the following components: 2 parts of sodium citrate, 2 parts of glucose, 3 parts of stabilizer, 25 parts of deionized water, by weight, citric acid is added to adjust the pH to 6, and the stabilizer is prepared by mixing dicetyl phosphate and phosphatidylserine in a mass ratio of 1:1), place it in an environment of 4°C, seal it and keep it away from light for later use.

[0055] Based on Example 1, a control experiment was carried out, specifically Comparative Examples 1 to 4, as described below:

[0056] Comparative Example 1: Comparative Example 1 is based on Example 1, with the following modifications: instead of preparing distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol, distearoylphosphatidylethanolamine-polyethylene glycol is directly used, and other processes remain unchanged, specifically:

[0057] S12: (1) Add 40 parts of hydrogenated lecithin, 12 parts of distearoylphosphatidylethanolamine-polyethylene glycol, and 12 parts of cholesterol to 150 parts of anhydrous ethanol by weight, stir and dissolve to obtain a lipid solution; (2) Heat the lipid solution to 60°C in a water bath, and then high-speed shear it at a speed of 13500 r / min. At the same time, add 200 parts of 225 mmol / L ammonium sulfate solution. After high-speed shearing for 20 minutes, extrude and filter it three times using an extruder to obtain a blank liposome crude product.

[0058] Comparative Example 2: Comparative Example 2 is based on Example 1, with the following adjustments: Buffer A includes the following components: 4 parts of histidine, 10 parts of sucrose, and 100 parts of deionized water, by weight, and other processes remain unchanged;

[0059] Comparative Example 3: Comparative Example 3 is based on Example 1, with the following modifications: directly preparing the doxorubicin liposome and water for injection into a high-stability doxorubicin liposome injection preparation, and other processes remain unchanged;

[0060] Comparative Example 4: Comparative Example 4 is based on Example 1, with the following adjustments: no stabilizer is added to buffer B, and other processes remain unchanged, specifically:

[0061] Buffer solution B includes the following components: 2 parts of sodium citrate, 1 part of glucose, 25 parts of deionized water, and citric acid is added to adjust the pH to 6.

[0062] In the above embodiments, all raw materials are from the following sources: distearoyl phosphatidylethanolamine-polyethylene glycol-carboxyl with a purity of 98%, CAS No.: 1403744-37-5, doxorubicin hydrochloride with a purity of 98%, all purchased from Zhengzhou Alpha Chemical Co., Ltd.; δ-tocopherol with a purity of 98%, histidine with a purity of 98%, all purchased from JACS-Zhengzhou Jacks Chemical Products Co., Ltd.; hydrogenated lecithin with a purity of 99%, cholesterol with a purity of 99%, ammonium sulfate with a purity of 99%, citric acid with a purity of 99%, sodium citrate with a purity of 99%, 4-dimethylaminopyridine with a purity of 99%, N,N'-dicyclohexylcarbodiimide with a purity of 99%, phosphatidylserine with a purity of 99%, all purchased from Hubei Yongkuo Technology Co., Ltd.; dicetyl phosphate with a purity of 98%, purchased from Hangzhou Disai Chemical Technology Co., Ltd.

[0063] Performance test: The high-stability doxorubicin liposome injection preparations prepared in Examples 1 to 3 and Comparative Examples 1 to 4 were subjected to stability tests, and the commercially available CAELYX doxorubicin injection preparations were used for comparison. The specific test method is: the injection preparations corresponding to each example are placed at 4°C for 1, 2, and 3 months, and the concentration changes of doxorubicin liposomes are determined by HPLC. The specific test results are shown in Table 1 below:

[0064] Table 1

[0065]

[0066] Result analysis: From the data in Table 1 above, it can be seen that the present invention prepares a high-stability doxorubicin liposome injection preparation, which has better stability than the commercially available CAELYX doxorubicin liposome injection preparation; after three months of storage, the doxorubicin liposome content is still 1.68 mg / mL, which is significantly higher than the 1.50 mg / mL of the commercially available doxorubicin liposome injection preparation. It further shows that the doxorubicin injection preparation prepared by the present invention has a stable structure, can be slowly released in the blood, and has a longer drug efficacy.

[0067] Finally, it should be noted that the above is only a preferred embodiment of the present invention, but the protection scope of this application is not limited thereto. Any changes or substitutions that can be easily thought of by any technician familiar with the technical field within the spirit and principle of the present invention and within the technical scope disclosed in this application should be included in the protection scope of this application; in the absence of conflict, the embodiments of this application and the features in the embodiments can be combined with each other. Therefore, the protection scope of this application shall be based on the protection scope of the claims.

Claims

1. A preparation process of a highly stable doxorubicin liposome injection preparation, characterized in that: The following steps are involved: S1: Preparation of doxorubicin liposomes: S11: distearoylphosphatidylethanolamine-polyethylene glycol-carboxyl and δ-tocopherol are reacted and grafted to obtain distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol; S12: mixing hydrogenated lecithin, distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol, cholesterol, anhydrous ethanol and ammonium sulfate, shearing and filtering to obtain a blank liposome crude product; S13: dialyzing the blank liposome crude product with buffer A to obtain a blank liposome suspension; S14: adding doxorubicin solution to the blank liposome suspension, heating and keeping warm, and then sterilizing and performing vacuum rotary evaporation to obtain doxorubicin liposomes; S2: prepare the doxorubicin liposomes and composite water for injection into a high-stability doxorubicin liposome injection preparation, and store it for future use.

2. The preparation process of a highly stable doxorubicin liposome injection preparation according to claim 1, characterized in that: The steps are specifically as follows: S1: Preparation of doxorubicin liposomes: S11: (1) adding 20 to 25 parts of distearoyl phosphatidylethanolamine-polyethylene glycol-carboxyl to 200 parts of dichloromethane by weight, stirring and dissolving, adding 5 to 8 parts of δ-tocopherol, 0.5 to 1 part of a catalyst, and 4 to 5 parts of a catalyst promoter, reacting at room temperature in the dark for 2 to 12 hours, ending the reaction, filtering, removing the filter residue, and collecting the filtrate; (2) pouring the filtrate into 200 parts of ether, standing at -20 to -5°C for 3 to 6 hours, filtering, removing the filtrate, collecting the filter residue, and drying to obtain distearoyl phosphatidylethanolamine-polyethylene glycol-tocopherol; S12: (1) adding 35-45 parts of hydrogenated lecithin, 10-15 parts of distearoylphosphatidylethanolamine-polyethylene glycol-tocopherol, and 10-15 parts of cholesterol to 150 parts of anhydrous ethanol by weight, stirring and dissolving, to obtain a lipid solution; (2) heating the lipid solution to 50-65° C. in a water bath, high-speed shearing at a speed of 10,000-15,000 r / min, and adding 200 parts of 200-250 mmol / L ammonium sulfate solution thereto, and after high-speed shearing for 10-30 min, extruding and filtering 2-3 times using an extruder to obtain a crude blank liposome; S13: dialyzing the blank liposome crude product with buffer A at room temperature to obtain a blank liposome suspension; S14: (1) adding doxorubicin hydrochloride to deionized water to prepare a doxorubicin solution with a concentration of 3 to 5 wt %; (2) adding doxorubicin solution to the blank liposome suspension, mixing evenly, heating the suspension in a water bath to 55-65° C. for 10-30 min, then cooling the suspension in an ice water bath to stop drug loading, sterilizing the suspension, and finally performing vacuum rotary evaporation at 25-30° C. to obtain doxorubicin liposomes, which were then stored at 2-5° C. for later use; S2: After preparing the doxorubicin liposomes and composite water for injection into a high-stability doxorubicin liposome injection preparation, place it at 2-5°C and seal it in the dark for future use.

3. The preparation process of a highly stable doxorubicin liposome injection preparation according to claim 2, characterized in that: In S13, the ratio of the blank liposome crude product to buffer A is 3 g:100 mL; wherein buffer A comprises the following components: by weight, 5 to 10 parts of sodium citrate, 2 to 5 parts of histidine, 5 to 15 parts of sucrose, and 100 parts of deionized water, and citric acid is added to adjust the pH to 5.5 to 6.

5.

4. The preparation process of a highly stable doxorubicin liposome injection preparation according to claim 2, characterized in that: In S14, the volume ratio of the blank liposome suspension to the doxorubicin solution is 10:

1.

5. The preparation process of a highly stable doxorubicin liposome injection preparation according to claim 2, characterized in that: In S12, the extruder is a liposome extruder; wherein the pore size of the filter membrane used is 0.05 to 0.45 μm.

6. The preparation process of a highly stable doxorubicin liposome injection preparation according to claim 2, characterized in that: In S11, the catalyst includes any one of 4-dimethylaminopyridine, 4-pyrrolidinopyridine, and 1-hydroxyphenyltriazole; the catalyst promoter includes any one of N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

7. The preparation process of a highly stable doxorubicin liposome injection preparation according to claim 2, characterized in that: In S2, the composite water for injection is obtained by mixing buffer solution B and water for injection in a volume ratio of 1:(1-2).

8. The process for preparing a highly stable doxorubicin liposome injection preparation according to claim 7, characterized in that: The buffer solution B comprises the following components: by weight, 1-2 parts of sodium citrate, 0.5-2 parts of glucose, 2-3 parts of stabilizer, 25 parts of deionized water, and citric acid is added to adjust the pH to 5.5-6.

5.

9. The preparation process of a highly stable doxorubicin liposome injection preparation according to claim 8, characterized in that: The stabilizer is obtained by mixing dicetyl phosphate and phosphatidylserine in a mass ratio of 1:

1.

10. The highly stable doxorubicin liposome injection preparation prepared by the preparation process according to any one of claims 1 to 9, characterized in that: In the high-stability doxorubicin liposome injection preparation, the concentration of doxorubicin liposome is 2 mg / mL.

Citation Information

Cited By

  • Doxorubicin hydrochloride liposome, preparation and application thereof

    CN120360948A

  • Preparation of doxorubicin and immunomodulator co-loaded liposome and synergistic anti-tumor application of doxorubicin and immunomodulator co-loaded liposome

    CN121337736A